Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
18 April 2023 - 3:31AM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today presented new
preclinical data generated from engineered CD28 bispecific
antibodies targeting the solid tumor antigens CEACAM5, ENPP3,
mesothelin, STEAP1 and Trop-2. For each molecule, in vitro T cell
activation was enhanced in combination with a CD3 T cell engager.
The data were presented in a poster titled “Tumor-specific CD28
costimulatory bispecific antibodies enhance T cell activation in
multiple solid tumors” (Abstract 2983) at the American Association
for Cancer Research (AACR) Annual Meeting in Orlando, Florida.
T cells in the tumor microenvironment require engagement of both
their T cell receptor (TCR) and their co-stimulatory receptors,
like CD28, to achieve full activation. The CD28 signal is
diminished in cancer because tumor cells do not typically express
CD28 ligands (i.e., CD80 and CD86), which leads to potentially
compromised activity of CD3 T cell engagers or anti-PD1 checkpoint
inhibitors.
Xencor has developed a modular XmAb® bispecific antibody
platform that allows for the rapid generation of drug candidates
that co-stimulate CD28 only in the presence of tumor cells and TCR
engagement. Xencor’s XmAb bispecific Fc domain serves as a scaffold
for a non-superagonist anti-CD28 binding domain and any
tumor-associated antigen of interest. Xencor’s Xtend™ Fc technology
further enhances circulating half-life of the antibody.
“Xencor has rapidly generated multiple CD28 co-stimulatory
bispecific antibodies with potential broad applicability across a
range of solid tumors, and each of these programs has demonstrated
compelling activity,” said John Desjarlais, Ph.D., executive vice
president and chief scientific officer at Xencor. “We are
leveraging the plug-and-play nature of our XmAb bispecific antibody
platforms to generate and explore additional CD28 drug candidates
against a broader universe of solid tumor targets.”
The poster will be archived under "Events & Presentations"
in the Investors section of the Company's website located at
www.xencor.com.
About XmAb808 (B7-H3 x CD28)
Xencor is conducting a Phase 1 study of XmAb808 in patients with
advanced solid tumors. XmAb808 is a tumor-selective, co-stimulatory
XmAb 2+1 bispecific antibody designed to bind to the broadly
expressed tumor antigen B7-H3 and selectively to the CD28 T-cell
co-receptor only when bound to tumor cells, which was demonstrated
in in vitro studies. Strong potentiation of checkpoint and CD3
cytotoxic activity was also observed in vivo. XmAb808 is a wholly
owned Xencor program.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
proteins structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact, and
can generally be identified by the use of words such as
“potential,” “can,” “will,” “plan,” “may,” “could,” “would,”
“expect,” “anticipate,” “seek,” “look forward,” “believe,”
“committed,” “investigational,” and similar terms, or by express or
implied discussions relating to Xencor’s business, including, but
not limited to, statements regarding research programs, the
quotations from Xencor's executive vice president and chief
scientific officer, and other statements that are not purely
statements of historical fact. Such statements are made on the
basis of the current beliefs, expectations, and assumptions of the
management of Xencor and are subject to significant known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements and the timing of
events to be materially different from those implied by such
statements, and therefore these statements should not be read as
guarantees of future performance or results. Such risks include,
without limitation, the risks associated with the process of
discovering, developing, manufacturing and commercializing drugs
that are safe and effective for use as human therapeutics and other
risks, including the ability of publicly disclosed preliminary
clinical trial data to support continued clinical development and
regulatory approval for specific treatments, in each case as
described in Xencor's public securities filings. For a discussion
of these and other factors, please refer to Xencor's annual report
on Form 10-K for the year ended December 31, 2022, as well as
Xencor's subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, as amended to
date. All forward-looking statements are qualified in their
entirety by this cautionary statement and Xencor undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230417005699/en/
For Investors: Charles Liles cliles@xencor.com 626-737-8118
For Media: Jason I. Spark Evoke Canale
jason.spark@evokegroup.com 619-849-6005
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Apr 2023 to Apr 2024